Summary: Listen to the Hidden in Plain Sight podcast episode, A New Approach to Mental Health with MAPS’ Rick Doblin, to learn about the final stretch of a three-decade journey to make MDMA-assisted psychotherapy an FDA-approved treatment option for PTSD. “Rick and MAPS have undertaken a huge project with an eye towards helping those by advancing modern medicine,” says Chad Grills, Mission CEO and host of the Hidden in Plain Sight podcast.
Originally appearing here.
More than three decades ago Dr. Rick Doblin began championing the use of a commonly known party drug as a potential treatment for patients suffering from emotional trauma. Now, 30 years later, that same drug enters a decisive stage in it’s potential widespread use.
Founded in 1986 by Doblin, Multidisciplinary Association for Psychedelic Studies (MAPS) serves to ensure that the potential of MDMA-assisted treatment continues to be taken seriously by researchers and by the FDA.
Now, after raising more than 80 million dollars during its 34-year run, the process of legalizing and creating access to this treatment has entered a critical stage: Phase Three Clinical trials where the treatment efficacy will ultimately dictate FDA approval. Early findings highlight that at least 90 percent of test subjects see statistically significant positive outcomes after the MDMA assisted treatments.
Rick and MAPS have undertaken a huge project with an eye towards helping those by advancing modern medicine. Today, he sits down with Chad to talk about these breakthroughs, what they mean for the future of this type of treatment, and why this movement matters.
